Imdelltra extends survival in relapsed small cell lung cancer, Korean investigator says
Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.
How this was made
The 30-second read
Why it matters
The data could accelerate regulatory discussions and drive near‑term share price appreciation.
Market read
First‑report of pivotal Phase 3 data for a novel SCLC therapy, likely to move Amgen's stock and influence the oncology biotech sector.
What to watch
Potential competition from other DLL3 agents and reimbursement uncertainties in key markets.
Background
Amgen presented the DeLLphi‑304 trial results at a press conference in Seoul, highlighting survival advantage over chemotherapy.
Ticker impact
Amgen's tarlatamab (Imdelltra) showed significant overall survival benefit in a Phase 3 trial for relapsed ES‑SCLC.
likely upward pressure as market prices in the survival benefit
The trial demonstrated a hazard ratio of 0.60 with median OS 13.6 vs 8.3 months, a material clinical win.
Market effects
Strengthens the DLL3‑targeted bispecific immunotherapy space and may lift peer biotech valuations.
Positive for Asian oncology markets where trial enrollment was significant.
Adds a new late‑line option for small‑cell lung cancer worldwide.
Counterpoint
If safety concerns or manufacturing scale‑up issues arise, the rally could be limited.
Key entities
- Key Opinion LeaderProfessor Ahn Myung‑ju
Lead investigator and author of the NEJM publication.
- CompanyAmgen
Developer of tarlatamab (Imdelltra).
